Correlation of ultrasound findings, liver and spleen cytology, and prognosis in the clinical staging of high metastatic risk canine mast cell tumors

Veterinary Radiology and Ultrasound

Volumn 52, Issue 5, 2011, Pages 548-554

  Book, Alison P ^a   Fidel, Janean ^b   Wills, Tamara ^b   Bryan, Jeffrey ^b   Sellon, Rance ^b   Mattoon, John ^b  

^a Veterinary Teaching Hospital   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Dog; Fine needle aspiration; Metastasis; Spleen

Indexed keywords

ANIMAL; ANIMAL DISEASE; ARTICLE; CYTODIAGNOSIS; DOG; DOG DISEASE; ECHOGRAPHY; LIVER; LIVER TUMOR; METASTASIS; PATHOLOGY; PROGNOSIS; SARCOMA; SKIN TUMOR; SPLEEN; SPLEEN TUMOR;

ANIMALS; CYTODIAGNOSIS; DOG DISEASES; DOGS; LIVER; LIVER NEOPLASMS; MAST-CELL SARCOMA; PROGNOSIS; SKIN NEOPLASMS; SPLEEN; SPLENIC NEOPLASMS;

CANIS FAMILIARIS;

EID: 80052935516     PISSN: 10588183     EISSN: 17408261     Source Type: Journal    
DOI: 10.1111/j.1740-8261.2011.01839.x     Document Type: Article

References (53)

1. London CA, Malpas PB, Wood-Follis SL, et al. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical incision. Clin Cancer Res 2009;15:3856-3865.
2. Hume CT, Kiupel M, Rigatti L, et al. Outcomes of dogs with grade 3 mast cell tumors: 43 cases (1997-2007). J Am Anim Hosp Assoc 2011;47:37-44.
3. Rassnick KM, Bailey DB, Russell DS, et al. A phase II study to evaluate the toxicity and efficacy of alternating CCNU and high-dose vinblastine and prednisone (CVP) for treatment of dogs with high-grade, metastatic or nonresectable mast cell tumours. Vet Comp Oncol 2010;8:138-152.
4. Rassnick KM, Bailey DB, Flory AB, et al. Efficacy of vinblastine for treatment of canine mast cell tumors. J Vet Intern Med 2008;22:1390-1396.
5. Thamm DH, Turek MM, Vail DM. Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases. J Vet Med Sci 2006;68:581-587.
6. Hahn KA, Ogilvie G, Rusk T, et al. Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med 2008;22:1301-1309.
7. Hillman LA, Garrett LD, de Lorimier LP, et al. Biological behavior of oral and perioral mast cell tumors in dogs: 44 cases (1996-2006). J Am Vet Med Assoc 2011;237:936-942.
8. London CA, Seguin B. Mast cell tumors in the dog. Vet Clin North Am Small Anim Pract 2003;33:473-489.
9. Macy DW. Canine mast cell tumors. Vet Clin North Am Small Anim Pract 1985;15:783-803.
10. Withrow SJ, Vail DM. Small animal clinical oncology, 4th ed. Philadelphia, PA: WB Saunders, 2007;402-404.
11. Bostock DE. The prognosis following surgical removal of mastocytomas in dogs. J Small Anim Pract 1973;14:27-41.
12. O'Keefe DA. Canine mast cell tumors. Vet Clin North Am Small Anim Pract 1990;20:1105-1115.
13. Dobson JM, Scase TJ. Advances in the diagnosis and management of cutaneous mast cell tumours in dogs. J Small Anim Pract 2007;48:424-431.
14. Murphy S, Sparkes AH, Smith KC, Blunden AS. Relationships between the histological grade of cutaneous mast cell tumours in dogs, their survival and efficacy of surgical excision. Vet Rec 2004;154:743-746.
15. Patnaik AK, Ehler WJ, MacEwen EG. Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs. Vet Pathol 1984;21:469-474.
16. Scase TJ, Edwards D, Miller J, et al. Canine mast cell tumors: correlation of apoptosis and proliferation markers with prognosis. J Vet Intern Med 2006;20:151-158.
17. Webster JD, Yuzbasiyan-Gurkan V, Thamm DH, et al. Evaluation of prognostic markers for canine mast cell tumors treated with vinblastine and prednisone. BMC Vet Res 2008;4.
18. Hottendorf GH, Nielsen SW. Pathologic report of 29 necropsies on dogs with mastocytoma. Vet Pathol 1968;5:102-121.
19. Seguin B, Leibman NF, Bregazzi VS, Ogilvie GK. Clinical outcome of grade II mast cell tumors treated with surgery alone in dogs: 55 cases (1996-1999). J Am Vet Med Assoc 2001;218:1120-1123.
20. Elston LB, Sueiro FA, Cavalcanti JN, Metze K. The importance of the mitotic index as a prognostic factor for survival of canine cutaneous mast cell tumors: a validation study. Vet Pathol 2009;46:362-364; author reply 364-365.
21. Romansik EM, Reilly CM, Kass PH, et al. Mitotic index is predictive for survival for canine cutaneous mast cell tumors. Vet Pathol 2007;44:335-341.
22. Ayl RD, Couto CG, Hammer AS, et al. Correlation of DNA ploidy to tumor histologic grade, clinical variables, and survival in dogs with mast cell tumors. Vet Pathol 1992;29:386-390.
23. Turrel JM, Kitchell BE, Miller LM, Théon A. Prognostic factors for radiation treatment of mast cell tumor in 85 dogs. J Am Vet Med Assoc 1988;194:936-940.
24. Gerritsen RJ, Teske E, Kraus JS, Rutteman GR. Multi-agent chemotherapy for mast cell tumours in the dog. Vet Quart 1998;20:28-31.
25. Jaffe MH, Hosgood G, Taylor HW, et al. Immunohistochemical and clinical evaluation of p53 in canine cutaneous mast cell tumors. Vet Pathol 2000;37:40-46.
26. Thamm DH, Mauldin EA, Vail DM. Prednisone and vinblastine chemotherapy for canine mast cell tumor-41 cases (1992-1997). J Vet Intern Med 1999;13:491-497.
27. Mullins MN, Dernell WS, Withrow SJ, et al. Evaluation of prognostic factors associated with outcome in dogs with multiple cutaneous mast cell tumors treated with surgery with and without adjuvant treatment: 54 cases (1998-2004). J Am Vet Med Assoc 2006;228:91-95.
28. Seguin B, Besancon MF, McCallan JL, Dewe LL. Recurrence rate, clinical outcome, and cellular proliferation indices as prognostic indicators after incomplete surgical excision of cutaneous Grade II mast cell tumors: 28 dogs. J Vet Intern Med 2006;20:933-940.
29. Sfiligoi G, Rassnick KM, Scarlett JM, et al. Outcome of dogs with mast cell tumors in the inguinal or perineal region versus other cutaneous locations: 124 cases (1990-2001). J Am Vet Med Assoc 2005;226:1368-1374.
30. Krick EL, Billings AP, Shofer FS, et al. Cytological lymph node evaluation in dogs with mast cell tumours: association with grade and survival. Vet Comp Oncol 2009;7:130-138.
31. Hahn KA, King GK, Carreras JK. Efficacy of radiation therapy for incompletely resected grade-III mast cell tumors in dogs: 31 cases (1987-1998). J Am Vet Med Assoc 2004;224:79-82.
32. Moriello KA, Rosenthal RC. Clinical approach to tumors of the skin and subcutaneous tissues. Vet Clin North Am Small Anim Pract 1990;20:1163-1190.
33. Owen L. (ed). TNM classification of tumours in domestic animals, 1st ed. Geneva: World Health Organization, 1980;14-15.
34. Stefanello D, Valenti P, Faverzani S, et al. Ultrasound-guided cytology of spleen and liver: a prognostic tool in canine cutaneous mast cell tumor. J Vet Intern Med 2009;23:1051-1057.
35. Finora K, Leibman NF, Fettman MJ, et al. Cytological comparison of fine-needle aspirates of liver and spleen of normal dogs and of dogs with cutaneous mast cell tumours and an ultrasonographically normal appearing liver and spleen. Vet Comp Oncol 2006;4:687-692.
36. Gieger T, Theon AP, Werner JA, et al. Biologic behavior and prognostic factors for mast cell tumors of the canine muzzle. J Vet Intern Med 2003;17:687-692.
37. Marconato L, Bettini G, Giocoboni C, et al. Clinicopathological features and outcome for dogs with mast cell tumors and bone marrow involvement. J Vet Intern Med 2008;22:1001-1007.
38. Cooper M, Tsai X, Bennett P. Combination CCNU and vinblastine chemotherapy for canine mast cell tumours: 57 cases. Vet Comp Oncol 2009;7:196-206.
39. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247.
40. Veterinary Co-operative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol 2004;2:195-213.
41. Baker-Gabb M, Hunt GB, France MP. Soft tissue sarcomas and mast cell tumours in dogs; clinical behaviour and response to surgery. Aust Vet J 2003;81:732-738.
42. Ishiguro T, Kadosawa T, Takagi S, et al. Relationship of disease progression and plasma histamine concentrations in 11 dogs with mast cell tumors. J Vet Intern Med 2003;17:194-198.
43. Cayatte SM, McManus P, Miller WH, Scott D. Identification of mast cells in buffy coat preparations from dogs with inflammatory skin diseases. J Am Vet Med Assoc 1995;206:325-326.
44. McManus PM. Frequency and severity of mastocytemia in dogs with and without mast cell tumors: 120 cases (1995-1997). J Am Vet Med Assoc 1999;215:355-375.
45. O'Keefe DA, Cuoto CG, Burke-Schwartz C, Jacobs RM. Systemic mastocytosis in 16 dogs. J Vet Intern Med 1987;1:75-80.
46. Stockham SL, Basel DL, Schmidt DA. Mastocytemia in dogs with acute inflammatory diseases. Vet Clin Pathol 1986;15:16-21.
47. Sato AF, Soloano MV. Ultrasonographic findings in abdominal mast cell disease: a retrospective study of 19 patients. Vet Radiol Ultrasound 2004;45:51-57.
48. Ballegeer EA, Forrest LJ, Dickinson RM, et al. Correlation of ultrasonographic appearance of lesions and cytologic and histologic diagnoses in splenic aspirates from dogs and cats: 32 cases. J Am Vet Med Assoc 2007;230:690-696.
49. Leveille R, Partington BP, Biller DS, Miyabayashi T. Complications after ultrasound-guided biopsy of abdominal structures in dogs and cats: 246 cases (1984-1991). J Am Vet Med Assoc 1993;203:413-415.
50. Wang KY, Dlp DL, Al-Rukibat RK, Radi ZA. Accuracy of ultrasound-guided fine-needle aspiration of the liver and cytologic findings in dogs and cats: 97 cases (1990-2000). J Am Vet Med Assoc 2004;224:75-78.
51. Camps-Palau MA, Leibman NF, Elmslie R, et al. Treatment of canine mast cell tumours with vinblastine, cyclophosphamide and prednisone: 35 cases. Vet Comp Oncol 2007;5:156-157.
52. Stockhaus C, Van Den Ingh T, Rothuizen J, Teske E. A multistep approach in the cytologic evaluation of liver biopsy samples of dogs with hepatic diseases. Vet Pathol 2004;41:461-470.
53. Vickery KR, Wilson H, Vail DM, Thamm DH. Dose-escalating vinblastine for the treatment of canine mast cell tumour. Vet Comp Oncol 2008;6:111-119.